secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001714899-24-000168
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q2 net loss $99M; FDA open to accelerated approval for DNL310; regains ATV:Abeta rights
--------------------------------------------------------------------------------

- Net loss $99.0M in Q2 2024 vs $183.4M net income in Q2 2023; no collaboration revenue versus $294.1M last year.
- Cash and marketable securities $1.35B as of June 30, 2024.
- FDA CDER open to discussing accelerated approval for DNL310 (MPS II) using CSF HS as surrogate biomarker.
- Biogen terminated ATV:Abeta license; Denali regains all rights; decision not related to efficacy or safety.
- DNL126 (MPS IIIA) selected for FDA START pilot program; Phase 1/2 data expected by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000168/0001714899-24-000168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000168/dnli-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer